Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
Alimta - Ontario Health (Cancer Care Ontario)
Product / population
Adult IV pemetrexed in the Cancer Care Ontario monograph. Local combination protocols can add separate modifications.
All record notes are retained here, including notes about sources not selected in this review.
Alimta - product and source limitations
The U.S. labeling directs withholding below CrCl 45. The dated Ontario monograph instructs discontinuation below that threshold. Verify the applicable treatment protocol before deciding whether treatment may resume.
What to reconcile: The U.S. labeling directs withholding below CrCl 45. The dated Ontario monograph instructs discontinuation below that threshold. Verify the applicable treatment protocol before deciding whether treatment may resume.
Ontario Health (Cancer Care Ontario) · Adult IV pemetrexed in the Cancer Care Ontario monograph. Local combination protocols can add separate modifications.
Renal method: Creatinine clearance in mL/min. Source date: CCO Formulary, April 2023. Retrieved: 2026-11-07
Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.
The monograph retains the previous pemetrexed dose when CrCl is at least 45 mL/min and directs discontinuation below 45. It calls for particular caution with NSAIDs at 45-79 mL/min. Confirm treatment eligibility and toxicity recovery before each cycle.
RDM73-alimta-professional-1 · Source locator: Dosage with Renal Impairment, page 7 of 11
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.
